Related references
Note: Only part of the references are listed.Hemoglobin A1c Reduction With the GLP-1 Receptor Agonist Semaglutide Is Independent of Baseline eGFR: post hoc Analysis of the SUSTAIN and PIONEER Programs
David Z. I. Cherney et al.
KIDNEY INTERNATIONAL REPORTS (2022)
Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease
Cristian Guja et al.
DIABETES THERAPY (2020)
Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial
Ofri Mosenzon et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
Katherine R. Tuttle et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)